A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection
Mark W. Kline(Tulane University), Seth Hetherington(Unknown), Ross E. McKinney(Environmental Protection Agency), James A. McDowell(Research Triangle Park Foundation), Mary Culnane(National Institute of Allergy and Infectious Diseases), Wayne M. Dankner(University of California San Diego), Suzette Blanchard(Rutgers, The State University of New Jersey), Jerry L. Shenep(St. Jude Children's Research Hospital), Russell B. Van Dyke(Tulane University), Richard C. Brundage(MelroseWakefield Healthcare), Andrea Kovács(University of Southern California), Courtney V. Fletcher(University of Nebraska at Omaha)
Cited by 41
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
|New England Journal of Medicine|1996|817
Antiretroviral Therapy during Pregnancy and the Risk of an Adverse Outcome
|New England Journal of Medicine|2002|347
Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2009|281